Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
31.50
-0.47 (-1.47%)
At close: Sep 18, 2026, 4:00 PM EDT
32.13
+0.63 (2.00%)
After-hours: Sep 18, 2026, 7:45 PM EDT
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $1.00M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $1.00M, down -93.33% year-over-year. In the year 2025, Zenas BioPharma had annual revenue of $10.00M with 100.00% growth.
Revenue (ttm)
$1.00M
Revenue Growth
-93.33%
P/S Ratio
2,053.07
Revenue / Employee
$5,988
Employees
167
Market Cap
2.05B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | 5.00M | 100.00% |
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ZBIO News
- 2 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Zenas BioPharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 days ago - Zenas BioPharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 9 days ago - Zenas BioPharma files to sell 7.0M shares of common stock for holders - TheFly
- 11 days ago - Zenas BioPharma Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 12 days ago - Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - GlobeNewsWire
- 12 days ago - Zenas BioPharma Slides: Corporate presentation - Filings
- 16 days ago - Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire